Gilead Dives After Its Bread-And-Butter Drug Misses Sales ForecastsInvestors Business Daily • 04/24/25
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?Zacks Investment Research • 04/22/25
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast CancerBusiness Wire • 04/21/25
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 EarningsZacks Investment Research • 04/18/25
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?Zacks Investment Research • 04/16/25
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025Business Wire • 04/10/25
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 04/09/25
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug ImportsInvestors Business Daily • 04/09/25
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 04/02/25
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksCNBC • 04/01/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing ApprovalSeeking Alpha • 03/23/25